- Home
- RDHL vs ALLR Comparison
RDHL vs ALLR Comparison
Compare RDHL & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- ALLR
- Stock Information
- Founded
- RDHL 2009
- ALLR 2004
- Country
- RDHL Israel
- ALLR United States
- Employees
- RDHL N/A
- ALLR N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- ALLR Health Care
- Exchange
- RDHL Nasdaq
- ALLR Nasdaq
- Market Cap
- RDHL 6.8M
- ALLR 6.0M
- IPO Year
- RDHL N/A
- ALLR N/A
- Fundamental
- Price
- RDHL $4.76
- ALLR $0.95
- Analyst Decision
- RDHL
- ALLR
- Analyst Count
- RDHL 0
- ALLR 0
- Target Price
- RDHL N/A
- ALLR N/A
- AVG Volume (30 Days)
- RDHL 9.0K
- ALLR 2.3M
- Earning Date
- RDHL 04-07-2025
- ALLR 03-07-2025
- Dividend Yield
- RDHL N/A
- ALLR N/A
- EPS Growth
- RDHL N/A
- ALLR N/A
- EPS
- RDHL N/A
- ALLR N/A
- Revenue
- RDHL $3,707,000.00
- ALLR N/A
- Revenue This Year
- RDHL $224.90
- ALLR N/A
- Revenue Next Year
- RDHL $82.69
- ALLR N/A
- P/E Ratio
- RDHL N/A
- ALLR N/A
- Revenue Growth
- RDHL N/A
- ALLR N/A
- 52 Week Low
- RDHL $4.76
- ALLR $0.90
- 52 Week High
- RDHL $20.28
- ALLR $264.00
- Technical
- Relative Strength Index (RSI)
- RDHL 26.11
- ALLR 40.42
- Support Level
- RDHL $5.20
- ALLR $0.91
- Resistance Level
- RDHL $5.50
- ALLR $1.03
- Average True Range (ATR)
- RDHL 0.23
- ALLR 0.09
- MACD
- RDHL -0.07
- ALLR -0.02
- Stochastic Oscillator
- RDHL 0.00
- ALLR 13.88
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.